Heron Therapeutics, Inc.

As of June 30, 2026, Heron Therapeutics Inc carries a market capitalization of 80.18M, placing it among publicly traded companies globally. Its enterprise value stands at 186.92M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Heron Therapeutics Inc's next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, Heron Therapeutics Inc has 189.46M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.52, and the price-to-book ratio stands at 13.69.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.24 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 186.92M versus a market cap of 80.18M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Heron Therapeutics Inc maintains a current ratio of 2.49, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -14.06, reflecting losses generated across the asset base. The company generates approximately 1.20M in revenue per employee across its workforce of 126.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.55 indicates how many times Heron Therapeutics Inc sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Heron Therapeutics Inc's stock has declined approximately 75.58% over the past 52 weeks. The 50-day moving average sits at 0.33, while the 200-day moving average is 0.74.

Over the twelve months ended June 30, 2026, Heron Therapeutics Inc generated 151.18M in revenue and converted that into -34.05M in net income, yielding earnings per share of -0.18. EBITDA reached -8.73M, while operating income came in at -10.86M.

As of June 30, 2026, Heron Therapeutics Inc holds 42.66M in cash and equivalents against 148.35M in total debt, resulting in a net debt position of 121.93M. Total book value stands at 5.86M, with working capital of 137.70M providing operational flexibility.

Heron Therapeutics Inc produced -11.61M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -529,000.00 in capital expenditures, free cash flow totaled -12.13M - equivalent to -0.07 per share.

Over the twelve months ended June 30, 2026, Heron Therapeutics Inc posted a gross margin of 70.07, reflecting its pricing power and cost economics. The operating margin of -7.19 and net profit margin of -22.52 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -15.53: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -16.98, meaning Heron Therapeutics Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Heron Therapeutics Inc's most recent stock split took place on January 13, 2014 with a 20:1 split ratio.

As of June 30, 2026, Heron Therapeutics Inc has an Altman Z-Score of -9.53, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.